title: Update and review of central retinal vein occlusion.
abstract: OBJECTIVE
  To review the clinical picture of central retinal vein occlusion (CRVO), with an emphasis on recent therapeutic developments.
  
  
  RESULTS
  The most significant advances with regard to CRVO relate to the establishment of the important role of intravitreal anti-vascular endothelial growth factor and corticosteroids in the treatment of macular edema associated with vein occlusion.
  
  
  CONCLUSIONS
  Important objectives on evaluation of a patient presenting with a CRVO include differentiation between ischemic and nonischemic types, identification of any complications, and establishment of a treatment and/or follow-up plan. Macular edema is one of the main causes of vision loss in CRVO, and for the first time we can have effective treatment options for affected patients.
authors: Retina Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
authors: Nikolas J S
authors: NJ
authors: London
authors: Gary
authors: G
authors: Brown
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy; D012170:Retinal Vein Occlusion / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A